Brought to you by 
Intarcia licenses Servier ex-US/Japan rights to Phase III diabetes therapy
25 Sep 2017
Executive Summary
In one of the largest ex-US biotech partnerships (possibly worth just over $1bn), Intarcia Therapeutics Inc. (drug delivery) granted Servier SA exclusive rights to develop and commercialize its Phase III Type II diabetes candidate ITCA650 (exenatide) worldwide excluding the US (where Intarcia keeps rights) and Japan (where the firm plans to find another partner).
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Controlled Release
-
Drug Delivery
-
Medical Devices
- Implantable Devices
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Intarcia licenses Servier ex-US/Japan rights to Phase III diabetes therapy
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice